Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.61 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.61 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 9/20 | 0.57 |
| ▸ | KDR | P35968 | 8/20 | 0.57 |
| ▸ | CDK4 | P11802 | 2/20 | 0.57 |
| ▸ | CCND1 | P24385 | 2/20 | 0.57 |
| ▸ | CCND3 | P30281 | 2/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 3/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 2/20 | 0.54 |
| ▸ | TTK | P33981 | 1/20 | 0.50 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932160 | 1.00 | NTRK1 (0.61) | NTRK1NTRK3NTRK2CHEK1KDR | |
| SCHEMBL25278552 | 0.85 | NTRK1 (0.55) | NTRK1NTRK3NTRK2TTKIP6K1 | |
| SCHEMBL627903 | 0.79 | TTK (0.59) | NTRK1TTKIP6K1 | |
| SCHEMBL5508123 | 0.78 | CHEK1 (0.61) | CHEK1KDRCDK4CCND1CCND3 | |
| SCHEMBL5508124 | 0.78 | CHEK1 (0.61) | CHEK1KDRCDK4CCND1CCND3 | |
| SCHEMBL5386440 | 0.78 | TTK (0.72) | NTRK1NTRK3NTRK2CDK2AURKB | |
| SCHEMBL2574384 | 0.78 | TTK (0.55) | NTRK1NTRK3NTRK2TTKIP6K1 | |
| SCHEMBL17982284 | 0.78 | TTK (0.55) | NTRK1NTRK3NTRK2TTKIP6K1 | |
| SCHEMBL27681104 | 0.77 | KDR (0.52) | NTRK1NTRK3NTRK2CHEK1KDR | |
| SCHEMBL3917601 | 0.77 | CHEK1 (0.67) | CHEK1KDRCDK4CCND1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732938-B1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-05-06 | — | — | EP | disclosed |
| US-7491710-B2 | Organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2009-02-17 | — | — | US | disclosed |
| CN-1894264-A | Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors | AVENTIS PHARMA SA (FR) | 2007-01-10 | — | — | CN | disclosed |
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | PPIP5K2, INPPL1, IP6K3 | NTRK1 1855/4885NTRK3 614/4885NTRK2 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.